The need for another typhoid fever vaccine

Journal of Infectious Diseases

Volumn 192, Issue 3, 2005, Pages 357-359

  Von Seidlein, Lorenz ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; TYPHOID VACCINE;

DRUG SAFETY; EDITORIAL; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; PRIORITY JOURNAL; SALMONELLA TYPHI; TYPHOID FEVER;

ADMINISTRATION, ORAL; ASIA; HUMANS; INCIDENCE; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 22544472120     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/431607     Document Type: Editorial

References (18)

1. Kirkpatrick BD, Tenney KM, Larsson CJ, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005; 191: 360-6 (in this issue).
2. Crump J, Luby S, Mintz E. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-53.
3. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-7.
4. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-49.
5. Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg 2004; 98:423-30.
6. Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98:413-22.
7. Vollaard A, Ali S, van Asten H, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 2004; 291:2607-15.
8. World Health Organization (WHO). Background document WHO/V&B/03.07: the diagnosis, treatment and prevention of typhoid fever. Geneva: WHO, 2003.
9. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-8.
10. Lin F, Ho V, Khiem H, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9.
11. Levine M, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21 a typhoid vaccine in a randomized controlled field trial. Lancet 1990; 336:891-4.
12. Hindle Z, Chatfield S, Phillimore J, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70:3457-67.
13. Patriarca P, Wright P, John T. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
14. McBean A, Thoms M, Albrecht P, Cuthie J, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128:615-28.
15. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007.
16. Chen RT, DeStefano F, Davis RL, et al. The vaccine safety datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000; 78:186-94.
17. Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders Company, 1999.
18. Yang J. An analysis of S. paratyphi A and S. typhi prevalence in Guangxi autonomous region between 1994-2002. China Trop Med 2004; 4:177-80.